In This Article:
What Happened?
Shares of lab services company Charles River Laboratories (NYSE:CRL) jumped 17.3% in the afternoon session after the company reported strong first quarter 2025 results which significantly beat analysts' organic revenue and EPS estimates, and featured a raise to full-year EPS guidance. Zooming out, we think this was a solid print.
The shares closed the day at $136.79, up 18.6% from previous close.
Is now the time to buy Charles River Laboratories? Access our full analysis report here, it’s free.
What The Market Is Telling Us
Charles River Laboratories’s shares are somewhat volatile and have had 13 moves greater than 5% over the last year. But moves this big are rare even for Charles River Laboratories and indicate this news significantly impacted the market’s perception of the business.
Charles River Laboratories is down 25% since the beginning of the year, and at $136.97 per share, it is trading 44.2% below its 52-week high of $245.29 from July 2024. Investors who bought $1,000 worth of Charles River Laboratories’s shares 5 years ago would now be looking at an investment worth $874.87.
Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.